Pfizer Strikes Deal With Impax Over Generic Detrol LA

Law360, New York (August 24, 2012, 7:06 PM EDT) -- Drug makers Pfizer Inc. and Impax Laboratories Inc have settled patent litigation over Impax's bid to produce a generic version of Pfizer's overactive-bladder drug Detrol LA, according to court papers filed Wednesday in New Jersey federal court.

The deal puts an end to the suit Pfizer filed in 2008 after Impax sought approvals from the U.S. Food and Drug Administration to market a generic Detrol LA.The settlement and license agreement between the companies include a permanent injunction blocking Impax from making knockoff versions of extended-release loiterodine, except as expressly permitted, while two of Pfizer's patents remain valid, court documents said....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!